Kristine Swiderek
Directeur/Membre du Conseil chez Sitka Biopharma, Inc.
Profil
Kristine Swiderek was the founder of OncoResponse, Inc. which was founded in 2015, where she held the title of Chief Scientific Officer from 2015 to 2017.
She is currently the Director at Sitka Biopharma, Inc. since 2017.
Dr. Swiderek's former positions include Vice President-Protein Science at ZymoGenetics, Inc., Chief Scientific Officer at Theraclone Sciences, Inc. from 2011 to 2017, and Senior Vice President-Research at Alpine Immune Sciences, Inc. from 2017 to 2020.
Dr. Swiderek earned a doctorate degree from Ruhr-Universität Bochum.
Postes actifs de Kristine Swiderek
Sociétés | Poste | Début |
---|---|---|
Sitka Biopharma, Inc.
Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Directeur/Membre du Conseil | 06/09/2017 |
Anciens postes connus de Kristine Swiderek
Sociétés | Poste | Fin |
---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/06/2020 |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Directeur Technique/Scientifique/R&D | 01/12/2017 |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Fondateur | 01/12/2017 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Formation de Kristine Swiderek
Ruhr-Universität Bochum | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Sitka Biopharma, Inc.
Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom. | Health Technology |